| Investigator |
NCT05106751: A Randomized, Multicenter, Evaluator-Blinded, Active-Controlled, Parallel-Group Investigation to Evaluate the Performance and Safety of YVOIRE® Classic Plus Versus Comparator for Temporary Correction of Nasolabial Folds |
|
|
| Completed | 4 | 104 | Europe | Hyaluronic acid dermal filler | LG Chem | Correction of Nasolabial Folds | 09/22 | 04/23 | | |
OPERA-T, NCT05238116 / 2021-004554-32: Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis ( Study) |
|
|
| Recruiting | 3 | 123 | Europe, Canada, US, RoW | PC945, Placebo | Pulmocide Ltd | Refractory IPA | 03/25 | 04/25 | | |
| Active, not recruiting | 3 | 94 | Europe, US, RoW | Hydroxypropyl-beta-cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc. | Niemann-Pick Disease, Type C1 | 06/25 | 06/26 | | |
| Recruiting | 3 | 528 | Europe, US, RoW | Cefepime-zidebactam (FEP-ZID), Meropenem | Wockhardt, Medpace, Inc. | Complicated Urinary Tract Infection, Acute Pyelonephritis | 12/24 | 12/24 | | |
Integral-1, NCT05887908: Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis |
|
|
| Active, not recruiting | 3 | 614 | Europe | co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, imipenem/cilastatin | Meiji Seika Pharma Co., Ltd. | Complicated Urinary Tract Infection, Acute Pyelonephritis | 11/24 | 11/24 | | |
Integral-2, NCT05905055 / 2021-001396-16: P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales |
|
|
| Recruiting | 3 | 150 | Japan | co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, BAT | Meiji Seika Pharma Co., Ltd., Japan Agency for Medical Research and Development | Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Complicated Intra-abdominal Infection | 02/25 | 02/25 | | |
EAD501, NCT05607615: A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease |
|
|
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
NCT06564311: A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) |
|
|
| Recruiting | 2 | 93 | Europe, US | Obexelimab, Placebo | Zenas BioPharma (USA), LLC | Relapsing Multiple Sclerosis | 08/25 | 12/25 | | |
NCT05113342: Descartes-25 in Relapsed/Refractory Multiple Myeloma |
|
|
| Terminated | 1 | 9 | US, RoW | Descartes-25, DC-25 | Cartesian Therapeutics | Multiple Myeloma, Relapse Multiple Myeloma | 05/23 | 11/24 | | |
SER-155-001, NCT04995653: A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT |
|
|
| Completed | 1 | 60 | US | Vancomycin Pre-Treatment, Vancomycin Placebo, SER-155, SER-155 Placebo | Seres Therapeutics, Inc., Memorial Sloan Kettering Cancer Center | Allogeneic Hematopoietic Stem Cell Transplantation | 07/24 | 07/24 | | |
NCT04784299: To Evaluate the Performance and Safety of YVOIRE Volume Plus for Improvement of Mid-face Volume |
|
|
| Active, not recruiting | N/A | 105 | Europe | YVOIRE volume plus, Restylane Lyft with Lidocaine | LG Chem | Midface Volume Deficit | 03/22 | 10/22 | | |
NCT05646641: Strength Training in Fibromyalgia on Balance, Neuromuscular Performance and Symptoms |
|
|
| Recruiting | N/A | 30 | RoW | Strength exercise | University of Beira Interior, Universidade Federal de Pernambuco | Fibromyalgia | 12/24 | 01/25 | | |
NCT05314504: Clinical Investigation of YVOIRE Y-Solution 360 for Lip Augmentation in China |
|
|
| Recruiting | N/A | 174 | RoW | YVOIRE Y-Solution 360 | LG Chem | Lip Augmentation | 12/23 | 08/24 | | |
| Recruiting | N/A | 132 | Europe | Remote monitoring, patientMpower app | Imperial College Healthcare NHS Trust, patientMpower Ltd., Imperial College London, University College, London, Action for Pulmonary Fibrosis | Interstitial Lung Disease | 01/25 | 04/25 | | |
| Okur, Ilyas |
| Active, not recruiting | 3 | 43 | Europe, Canada, Japan, US, RoW | Venglustat, imiglucerase, Cerezyme® | Sanofi, Sanofi-aventis recherche & développement | Gaucher's Disease Type III | 09/25 | 10/26 | | |
| Sari, Sinan |
NCT00246857: Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death |
|
|
| Recruiting | N/A | 5000 | US, RoW | | National Institute of Allergy and Infectious Diseases (NIAID) | Primary Immune Deficiency | | | | |
| Karakan, Tarkan |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Not yet recruiting | N/A | 54 | NA | Aronia juice, Mediterranean diet, Low-fat diet | Istanbul Kent University | Non-Alcoholic Fatty Liver Disease | 09/25 | 06/26 | | |
| Acet, Nagihan |
NCT04794647: The Effects of Manual Therapy on Balance and Cervical Proprioception |
|
|
| Completed | N/A | 66 | RoW | Cervical mobilization, Manual therapy, Placebo mobilization | Gazi University | Neck Pain | 01/21 | 01/21 | | |
NCT06558318: TMJ Dysfunction: Effects on Proprioception, Pain, and Body Awareness |
|
|
| Active, not recruiting | N/A | 60 | RoW | Assessment of temporomandibular dysfunction | Nagihan Acet | Temporomandibular Joint Disorders, Temporomandibular Disorder | 12/24 | 01/25 | | |
| Enrolling by invitation | N/A | 60 | RoW | Assessment of cervical proprioception | Nagihan Acet | Cervical Proprioceptive Error in Healthy Young Individuals | 01/25 | 02/25 | | |
NCT06598774: Cervical Parameters and Body Awareness in Relation to Smartphone Addiction |
|
|
| Active, not recruiting | N/A | 40 | RoW | Assessment of head posture:, Assessment of Cervical Pain Pressure Threshold, Assessment of general cervical mobility, Assessment of upper cervical mobility, Assessment of Body Awareness | Nagihan Acet | Smartphone Addiction | 11/24 | 12/24 | | |
NCT06603493: Headaches: Effects on Sleep, Sensitization, and Psychological Factors |
|
|
| Active, not recruiting | N/A | 40 | RoW | Assessment of sleep disorders, Assessment of Central Sensitization, Assessment of depression, anxiety and stress levels | Nagihan Acet | Headache Disorder | 11/24 | 12/24 | | |
NCT06689319: Factors Linked to AI Literacy in University Students |
|
|
| Not yet recruiting | N/A | 184 | RoW | Assessment of Artificial Intelligence Literacy | Nagihan Acet | Technology Literacy, Reading Habits, Smartphone Addiction, Internet Addiction, Academic Acheivement | 03/25 | 04/25 | | |
| Ozkurt, Zubeyde |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
| Wen, Shujuan |
NCT06521255: Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 244 | RoW | Tafasitamab, Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | DLBCL | 09/28 | 12/29 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 02/25 | 08/28 | | |
ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2/3 | 226 | RoW | ICP-248, Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematologic Malignancies | 11/30 | 07/31 | | |
TQB3702-II-02, NCT06566586: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma |
|
|
| Recruiting | 2 | 80 | RoW | TQB3702 tablets+Chemotherapy regimen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | B-cell Lymphoma | 03/26 | 12/27 | | |
NCT05978739: Evaluating Different Doses of Orelabrutinib in MCL |
|
|
| Recruiting | 2 | 40 | RoW | Orelabrutinib High dose, Orelabrutinib Low dose | InnoCare Pharma Inc., Beijing InnoCare Pharma Tech Co., Ltd. | Mantle Cell Lymphoma | 02/25 | 05/25 | | |
NCT05257018: R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse |
|
|
| Recruiting | 2 | 83 | RoW | R-CDOP+intrathecal MTX, Pegylated liposome doxorubicin（PLD） | Fudan University | Diffuse Large B-cell Lymphoma | 01/26 | 01/28 | | |
| DEMİRDAĞ, Erhan |
NCT03676907: Assessment of Single and Double Layer Suturation of Lower Segment Uterine Incision by USG After C/S |
|
|
| Completed | N/A | 56 | RoW | double layer suturation technique | Gazi University | Uterine Scar | 07/23 | 07/23 | | |
| Tutal, Anıl Doğukan |
NCT03676907: Assessment of Single and Double Layer Suturation of Lower Segment Uterine Incision by USG After C/S |
|
|
| Completed | N/A | 56 | RoW | double layer suturation technique | Gazi University | Uterine Scar | 07/23 | 07/23 | | |
| Karabacak, Recep Onur |
NCT03676907: Assessment of Single and Double Layer Suturation of Lower Segment Uterine Incision by USG After C/S |
|
|
| Completed | N/A | 56 | RoW | double layer suturation technique | Gazi University | Uterine Scar | 07/23 | 07/23 | | |
| Yağcı, Munci |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 02/25 | 08/28 | | |
| Arıkan, Sefik Murat |
| Recruiting | N/A | 40 | RoW | Moment Tumour Hip Prothesis | Estas Tıbbi Mamülleri Medikal, Klinar CRO | Primary and Secondary Bone Tumor in the Proximal Femur Region | 12/24 | 08/25 | | |
